Reality of secondary prevention pharmacological therapy of cardiovascular diseases in the city of Embu-Guaçu/SP
DOI:
https://doi.org/10.13037/ras.vol19n67.6553Keywords:
cardiovascular agentes, cardiovascular dieeases, secondary preventionAbstract
not only to decrease cardiovascular disease (CVD) morbidity and mortality, but also because it has an impact on quality of life. Objectives: The aim of this study was to evaluate secondary prevention drug therapy in patients with cardiovascular events who attend the Family Health Units of Embu-Guaçu. Patients and Methods: An observational, cross-sectional study was conducted with 68 patients who had experienced at least one cardiovascular event and who answered a questionnaire including socio-demographic data, cardiovascular event identification, prescribed medications, prescribers, and place of follow-up. Results: Among the cardiovascular events, stroke was the most prevalent (p <0.0001) followed by Acute Myocardial Infarction - AMI. Only 21% of prescriptions were adequate; the majority of the participants were accompanied by the cardiologist. Of the patients followed by primary healthcare, only 26% received the appropriate prescription. Conclusions: Secondary prevention drug therapy of patients studied at these Basic Health Units in the municipality of Embu-Guaçu is far from being considered ideal, as only 26% of the prescriptions were adequate according to the guidelines on secondary prevention drug therapy for CVD, and below some studies that report up to 90%.
Downloads
References
Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm J-D, et al. Reducing the global burden of cardiovascular disease, part 2: Prevention and treatment of cardiovascular disease. Circulation 2017;121(6):695-710.
Souza RKT, Bortoletto MSS, Loch RM, González DA, Matsuo T, Cabrera MAS, et al. Prevalência de fatores de risco cardiovascular em pessoas com 40 anos ou mais de idade, em Cambé, Paraná (2011): estudo de base populacional. Epidemiol Serv Saúde. 2013; 22(3):435-44.
Chen CXR, Chan SL, Law TC, Choi SK, Chan KH. Secondary prevention of stroke: na evidence-based clinical audit in the primary care. Hong Kong Med J. 2011;17:469-77.
Mansur AP, Favarato D. Mortalidade por doenças cardiovasculares no Brasil e na região metropolitana de São Paulo: atualização 2011. Arq Bras Cardiol. 2012; 99(2):755-61.
World Health Organization. (WHO). Global status report on noncommunicable diseases 2010: Description of the global burden of NCDs, their risk factors and determinants.[periódico na internet]. 2011Apr [ acesso em 2016 Apr 17].[aproximadamente 176 p.]. Disponível em: http://www.who.int/nmh/publications/ncd_report2010/en/
Bansilal S, Castellano JM, Fuster V. Gloval Burden of CVD: focus on secondary of cardiovascular disease. Int J Cardiol. 2015;201(1): S1-7.
Piegas, LS, Timerman, A, Feitosa, GS, Nicolau, JC, Mattos, LAP, Andrade, MD. V Diretriz da Sociedade Brasileira de Cardiologia sobre Tratamento do Infarto Agudo do Miocárdio com Supradesnível do Segmento ST. Arq Bras Cardiol. 2015;105(2, Suppl. 1),1-121.
Brotons C, Maiques A, Mostaza J, Pinto X, Vilaseca J. Control lipídico en prevención secundaria: estudio multicéntrico, observacional en atención primaria. Aten Prim. 2004;34(2):81-6.
SicrasMainar A, VelascoVelasco S, GonzálezRojas GN; ClementeIgeño C, RodríguezCid JL. Influencia de la morbilidad, control metabólico y uso de recursos de los sujetos ensituación de riesgo cardiovascular en el ámbito de la atención primaria de salud. Aten Primaria. 2008;40(9):447-54.
Poredos P, Jezovnik MK. Do the effects of secondary prevention of cardiovascular events in PAD patients differ from other atherosclerotic disease. Int J Mol Sci. 2015;16:14477-89.
Brasil CKOI, Avezum Jr A, Uint L, Del Monaco MI, Barros VM, Campos SYR, et al. Cardiovascular prevencion in coronary heart disease patients: guidelines implementacion in clinical practice. Rev Bras Cir Cardiovasc. 2013;28(2):238-47.
Therapeutic guidelines cardiovascular, 6th edn. Melbourne, Vic: Cardiovascular Expert Group. Therapeutic Guidelines, 2012.
Delsart P, Lemesle G, Lamblin N, Tricot O, Meurice T, Mycinski C, et al. Secondary medical prevention and clinical outcome in coronary artery disease patients with a history of non-coronary vascular intervention: a report from the CORONOR investigators. Eur J Prevent Cardiol. 2015;22(7):864-71.
Lieshout van J, Grol R, Campbell S, Falcoff H, Capell EF, Glehr M, et al. Cardiovascular risk management in patients with coronary heart disease in primary care: variation across countries and practices. An observational study based on quality indicators. BMC Fam Pract.
;13:96-103.
Instituto Brasileiro de Geografia e Estatística. Disponível em: http://cidades.ibge.gov.br/
Berwanger O, Mattos LAP, Martin JFV, Lopes RD, Figueiredo EL, Magnoni D, Precoma DB, Machado CA, Guimarães JI, Andrade JP. Prescrição de terapias baseadas em evidências para pacientes de alto risco cardiovascular: estudo REACT. Arq.Brasil. de Cardiologia. 2013;100(33):212-220.
Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636-48.
Munoz MA, Subirana I, Ramos R, Franzi A, Vila J, Marrugat J. Med Clin (Barc). Eficacia de um programa intensivo de prevenciòn secundaria de cardiopatia isquêmica tras 5 anos de intervención. 2008;130(14):521-5.
Simão AF, Precoma DB, Andrade JP, Correa Filho H, Saraiva JFK, Oliveira GMM, et al. I Diretriz brasileira de prevenção cardiovascular. Arq Bras Cardiol. 2013; 101(6):2-50.
Sex differences in the presentation and perception of symptoms among young patients with Myocardial Infarction: Evidence from VIRGO Study (Variation in Recovery: Role of gender on outcomes of young AMI patients). Circulation 2018;137(8):781-790.
Bhatnagar P, Wickramasinghe K, Williams J, Rayner M, Townsend N. The epidemiology of cardiovascular disease in the UK 2014. Heart 2015;101:1182-89.
Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Ver Cardiol. 2014;11:276-89.
Mendis S, Abegunde D, Yussuf S, Ebrahim S, Shaper G, Ghannem H, et al. WHO study on Prevention of Recurrences of Myocardial Infarction and Stroke (WHO PREMISSE). Bull World Health Organization. 2005;83(11):820-9.
Yssuf S, Islam S, Chow CK, Rangarajan S, Dagenais , Diaz R, et al. Use of Secundary Prevention Drugs for Cardiovascular Disease in the Community in High-income, Middle-income, and Low-income Countries (the PURE Study): a propesctive epidemiological survey. Lancet 2011;378(9798):1231-43.
Hawkins NM, Scholes S, Bajekal M, Love H, O’Flaherty M, Raine R, Capewell S. The UK National health service: delivering equitable treatment across the spectrum of coronary disease. Circ Cardiovasc Qual Out. 2013;6:208-16.
Escolano ER, Beltran DO, Tortosa MG, Palaón NA, Fort AC, Pérez JN, et al. El estúdio PROPESE: resultados de um novo modelo oeganizativo em atención primaria para para pacientes com cardiopatia isquêmica crónica basado em uma intervención multifactorial. Aten Primaria. 2014;46(supl 3):10-5.
Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatmentof coronary heart disease by implementation of Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87(7):819-22.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Revista de Atenção à Saúde
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Policy Proposal for Journals offering Free Delayed Access
Authors who publish in this magazine agree to the following terms:
- Authors maintain the copyright and grant the journal the right to the first publication, with the work simultaneously licensed under a Creative Commons Attribution License after publication, allowing the sharing of the work with recognition of the authorship of the work and initial publication in this journal.
- Authors are authorized to assume additional contracts separately, for non-exclusive distribution of the version of the work published in this magazine (eg, publishing in institutional repository or as a book chapter), with the acknowledgment of the authorship and initial publication in this journal.
- Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes, as well as increase impact and citation of the published work (See The Effect of Open Access).
